miR-155 regulative network in FLT3 mutated acute myeloid leukemia

被引:22
|
作者
Salemi, Domenico [1 ]
Cammarata, Giuseppe [2 ]
Agueli, Cecilia [1 ]
Augugliaro, Luigi [3 ]
Corrado, Chiara [5 ]
Bica, Maria Grazia [1 ]
Raimondo, Stefania [5 ]
Marfia, Anna [1 ]
Randazzo, Valentina [1 ]
Dragotto, Paola [1 ]
Di Raimondo, Francesco [4 ]
Alessandro, Riccardo [5 ]
Fabbiano, Francesco [1 ]
Santoro, Alessandra [1 ]
机构
[1] AO Osped Riuniti Villa Sofia Cervello, Div Ematol Con UTMO, Palermo, Italy
[2] IBIM CNR, Palermo, Italy
[3] Univ Palermo, Dipartimento Sci Stat & Matemat Silvio Vianelli, I-90133 Palermo, Italy
[4] PO Ferrarotto Catania, Div Ematol, Catania, Italy
[5] Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biol & Genet, Palermo, Italy
关键词
Network; MicroRNA; AML; INTERNAL TANDEM DUPLICATION; MICRORNA EXPRESSION PROFILES; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-GROWTH; DIFFERENTIATION; TARGET; IDENTIFICATION; PROLIFERATION; SUPPRESSION;
D O I
10.1016/j.leukres.2015.04.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute myeloid leukemia (AML) represents a heterogeneous disorder with recurrent chromosomal alterations and molecular abnormalities. Among AML with normal karyotype (NK-AML) FLT3 activating mutation, internal tandem duplication (FLT3-ITD), is present in about 30% of patients, conferring unfavorable outcome. Our previous data demonstrated specific up-regulation of miR-155 in FLT3-ITD+ AML. miR-155 is known to be directly implicated in normal hematopoiesis and in some pathologies such as myeloid hyperplasia and acute lymphoblastic leukemia. Methods and results: To investigate about the potential influence of miR-155 de-regulation in FLT3-mutated AML we generated a transcription factors regulatory network and combined this with data from multiple sources that predict miR-155 interactions. From these analyses, we derived a sub-network, called "miR-155 module" that describes functional relationship among miR-155 and transcription factorsin FLT3-mutated AML. We found that "miR-155 module" is characterized by the presence of six transcription factors as central hubs: four miR-155 regulators (JUN, RUNX1, FOSb, JUNB) and two targets of miR-155 (SPI1, CEBPB) all known to be "master" genes of myelopoiesis. We found, in FLT3-mutated AML, a significant down-regulation of miR-155 target genes CEBPB and SPI1 and up-regulation of miR-155 regulator genes JUN and RUNX1. We also showed that PKC412-related FLT3 inhibition, in MV4-11 cell line, causes down-regulation of miR-155 and increased level of mRNA and protein of miR-155 target SPI1. We showed in experiments of miR-155 mimic in K562 cell line, a high increase of miR-155 and an inverse correlation with the mRNA levels of its targets SPI1 and CEBPB. Moreover silencing of miR-155 in primary AMLs causes mRNA up-regulation of its target SPI1 and CEBPB. Conclusion: Our results suggest that activating mutation of FLT3 in AML can lead, through the induction of JUN, to an increased expression of miR-155, which then causes down-regulation of SPI1 and CEBPB and consequently may causes block of myeloid differentiation. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:883 / 896
页数:14
相关论文
共 50 条
  • [11] FLT3 Inhibition in Acute Myeloid Leukemia
    Smith, Catherine C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S5 - S6
  • [12] FLT3 inhibitors in acute myeloid leukemia
    Wu, Mei
    Li, Chuntuan
    Zhu, Xiongpeng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [13] FLT3 Inhibitors in Acute Myeloid Leukemia
    Stone, Richard M.
    ONCOLOGIST, 2016, 21 : S2 - S2
  • [14] FLT3 inhibitors in acute myeloid leukemia
    Mei Wu
    Chuntuan Li
    Xiongpeng Zhu
    Journal of Hematology & Oncology, 11
  • [15] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Abhishek Maiti
    Courtney D. DiNardo
    Naval G. Daver
    Caitlin R. Rausch
    Farhad Ravandi
    Tapan M. Kadia
    Naveen Pemmaraju
    Gautam Borthakur
    Prithviraj Bose
    Ghayas C. Issa
    Nicholas J. Short
    Musa Yilmaz
    Guillermo Montalban-Bravo
    Alessandra Ferrajoli
    Elias J. Jabbour
    Nitin Jain
    Maro Ohanian
    Koichi Takahashi
    Philip A. Thompson
    Sanam Loghavi
    Kathryn S. Montalbano
    Sherry Pierce
    William G. Wierda
    Hagop M. Kantarjian
    Marina Y. Konopleva
    Blood Cancer Journal, 11
  • [16] FLT3 inhibitors in acute myeloid leukemia
    不详
    ANNALS OF HEMATOLOGY, 2008, 87 : S87 - S89
  • [17] FLT3 Inhibitors for Acute Myeloid Leukemia
    Lancet, Jeffrey E.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 573 - 575
  • [18] FLT3 inhibitors in acute myeloid leukemia
    Pastore, Domenico
    DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2016, 4 (01): : 14 - 21
  • [19] FLT3 inhibitors in acute myeloid leukemia
    el-Shami, Khaled
    Stone, Richard M.
    Smith, B. Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (02) : 153 - 160
  • [20] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval G.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Loghavi, Sanam
    Montalbano, Kathryn S.
    Pierce, Sherry
    Wierda, William G.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD CANCER JOURNAL, 2021, 11 (02)